Article Versions Notes

Runzer-Colmenares FM, Ruiz R, Maco L, Maldonado M, Puma-Villanueva L, Galvez-Nino M, Aliaga C, Benites-Zapata VA, Diaz-Arocutipa C, Mas L, et al. Comparison of Erlotinib vs. Osimertinib for Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Without Prior Treatment: A Network Meta-Analysis. Cancers. 2025; 17(11):1895. https://doi.org/10.3390/cancers17111895

Runzer-Colmenares, Fernando M., Rossana Ruiz, Lorenzo Maco, Mike Maldonado, Luis Puma-Villanueva, Marco Galvez-Nino, Carlos Aliaga, Vicente A. Benites-Zapata, Carlos Diaz-Arocutipa, Luis Mas, and et al. 2025. "Comparison of Erlotinib vs. Osimertinib for Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Without Prior Treatment: A Network Meta-Analysis" Cancers 17, no. 11: 1895. https://doi.org/10.3390/cancers17111895

Runzer-Colmenares, F. M., Ruiz, R., Maco, L., Maldonado, M., Puma-Villanueva, L., Galvez-Nino, M., Aliaga, C., Benites-Zapata, V. A., Diaz-Arocutipa, C., Mas, L., & Urrunaga-Pastor, D. (2025). Comparison of Erlotinib vs. Osimertinib for Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer Without Prior Treatment: A Network Meta-Analysis. Cancers, 17(11), 1895. https://doi.org/10.3390/cancers17111895